As a matter of fact, these attempts have been very successful since several GLP-1 analogs have been developed and are currently widely used for the treatment of type 2 diabetes (T2D) and obesity, given their effectiveness in improving glycemic control and inducing weight loss [24]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.